// App-Quantinova.ai

781TiP : Apatinib and irinotecan combination treatment in first-line chemotherapy refractory esophageal squamous cell carcinoma: A phase I dose escalation study

Researchers

Presenter

  • J.Jia

Principal Investigators

  • Z.Sun

  • Y.Yang

  • C.Liu

  • Y.Xiao

  • X.Zhang

Medical Centers

  • VIP-2 GI Division of Medical Department, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Kinase Insert Domain Receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Irinotecan

  • L-Tyrosine

  • Apatinib

  • taxane

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved